KOS AI Unveils Argus: Revolutionary Non-Invasive Blood Glucose Monitoring Device

Image: https://www.globalnewslines.com/uploads/2025/03/1742033679.jpg

KOS AI

Image: https://www.globalnewslines.com/uploads/2025/03/85126c92279af75fc90fe201079c15bd.jpg

KOS AI has unveiled Argus, a revolutionary non-invasive blood glucose monitoring device that uses advanced optical sensing and artificial intelligence to measure blood glucose levels without needles or invasive sensors. This wrist-worn device represents a significant advancement in diabetes management technology, offering users a pain-free alternative to traditional glucose monitoring methods.

Shalal Habib, CEO of KOS AI, emphasized the transformative nature of the device: "The KOS Argus transforms glucose monitoring from a painful, intermittent process into a seamless, continuous experience. Our technology eliminates the pain and inconvenience of finger pricks while providing reliable glucose readings that can help people better manage their health."

Abhinav Agarwal, Head of Machine Learning at KOS AI, explained the innovative approach: "We've pioneered a fundamentally different approach to glucose monitoring that combines multi-dimensional signal processing with advanced machine learning architectures. By analyzing subtle variations across multiple wavelengths and applying our custom-designed deep learning models, we've achieved a level of accuracy that was previously thought impossible without invasive sensors."

Key features of the KOS Argus include:

*
Multi-wavelength photoplethysmography (PPG) technology with precision optical sensors

*
Sophisticated AI algorithms for accurate glucose readings

*
Continuous monitoring with real-time glucose readings throughout the day

*
Trend analysis to identify patterns and alert users to potential issues

*
Additional vital sign monitoring including heart rate, SpO2, and blood pressure

Initial internal testing has shown promising results:

*
91.3% classification accuracy in identifying glucose ranges

*
93.5% sensitivity for detecting hypoglycemia

*
97.2% specificity for hypoglycemia detection

*
92.6% of readings in Zone A and 7.1% in Zone B on Clarke Error Grid analysis

The device is currently undergoing formal clinical trials to validate these results in real-world conditions. KOS AI aims to make the Argus available to consumers in Q3 2025, with a version for clinical healthcare providers planned for release by the end of the year.

This non-invasive glucose monitoring technology has the potential to transform diabetes management for millions of people worldwide, offering a painless, continuous, and more convenient alternative to traditional finger prick tests.
Media Contact
Company Name: Nexus PR
Email: Send Email [http://www.universalpressrelease.com/?pr=kos-ai-unveils-argus-revolutionary-noninvasive-blood-glucose-monitoring-device]
Country: United States
Website: http://nexuspr.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.